Skip to main
  1. Stocks
  2. NeoGenomics
  3. Forecast
NEO

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics is benefiting from a durable shift toward higher-value NGS and MRD testing, with Q3 revenue of about $209M and NGS growth of +29% driving ASPs to $530 per test and lifting gross margin to 48.6% and EBITDA margin to 8.9%. The company’s improving execution is reinforced by repeated top-line beats, raised FY26 guidance to $807M-$809M, and strong cash generation, while the smaller biopharma segment continues to shrink as a share of revenue. Its outlook is further supported by expanding reimbursement for RaDaR ST and PanTracer LBx, which broadens the addressable MRD market and could sustain growth, mix improvement, and margin expansion over time.

Bears say

NeoGenomics is facing a difficult competitive landscape as private specialty labs and other precision oncology rivals gain share through stronger patient data leverage, more advanced NGS reports, and aggressive commercial tactics that can erode legacy testing volumes. Its financial profile also appears fragile, with operations running near breakeven on an Adj. EPS and EBITDA basis, leaving limited margin for error and no assurance of durable profitability. Additional downside comes from potential Medicare pricing cuts, slower innovation versus leading competitors, and execution risk tied to Tempus, where volatile pharma budgets, significant losses since inception, and debt could further pressure growth and sentiment.

NeoGenomics (NEO) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

NeoGenomics (NEO) Analyst Forecast & Price Prediction

Get the latest NeoGenomics (NEO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NeoGenomics (NEO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Strong Buy based on their latest research and market trends.

According to 7 analysts, NeoGenomics (NEO) has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


NeoGenomics (NEO) Analyst Forecast & Price Prediction

Get the latest NeoGenomics (NEO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NeoGenomics (NEO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NEO stock data and trends